サンプル依頼リスト カート
  • English
  • Korean
市場調査レポート
商品コード
1420460

セラノスティクスの世界市場 (～2028年)：製品 (画像診断・放射性医薬品・バイオマーカースクリーニング・ソフトウェア)・用途・ステークホルダー別

Theranostics Market by Product (Diagnostic imaging, Radiopharmaceuticals, Biomarker screening, Software), Application, & Stakeholder Expectations - Global Forecast to 2028
出版日: | 発行: MarketsandMarkets | ページ情報: 英文 194 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
セラノスティクスの世界市場 (～2028年)：製品 (画像診断・放射性医薬品・バイオマーカースクリーニング・ソフトウェア)・用途・ステークホルダー別
出版日: 2024年01月30日
発行: MarketsandMarkets
ページ情報: 英文 194 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

レポート概要

調査範囲
調査対象年 2021-2028年
基準年 2022年
予測期間 2023-2028年
単位 金額 (米ドル)
セグメント 製品・用途・エンドユーザー・地域
対象地域 北米・欧州・アジア太平洋・その他の地域

世界のセラノスティクスの市場規模は、2023年の21億米ドルから、予測期間中は15.5%のCAGRで推移し、2028年には43億米ドルの規模に成長すると予測されています。

R&D活動の増加、臨床試験数の増加、政府の取り組みなどが同市場の成長に寄与しています。

製品別では、放射性医薬品の部門が2022年に最大のシェアを示しています。この大きなシェアは、セラノスティクスの採用が増加していることと、癌などの慢性疾患の有病率が増加していることに起因しています。

用途別では、前立腺癌の部門が予測期間中、最大のCAGRを記録すると予測されています。癌人口の増加や、他の用途におけるセラノスティクスの利点を知るための進行中の臨床試験などの要因が、市場の成長を促進しています。

地域別では、アジア太平洋地域が予測期間中に最大の成長を示すと予測されています。その主な理由は、進化するヘルスケアインフラと同地域における主要企業の焦点の増加です。中国やインドなどの新興国のヘルスケアインフラは急速なペースで進化しており、病院やその他のエンドユーザーによる大規模な投資に繋がっています。これらの要因が同地域の市場成長を促進すると予想されています。

当レポートでは、世界のセラノスティクスの市場を調査し、市場概要、市場影響因子および市場機会の分析、特許の動向、法規制・償還環境、ケーススタディ、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
  • 価格分析
  • バリューチェーン分析
  • エコシステム/市場マップ
  • サプライチェーン分析
  • ポーターのファイブフォース分析
  • 規制状況
  • セラノスティクス市場のタイムライン
  • 償還分析
  • 貿易分析
  • 特許分析
  • ケーススタディ分析
  • 主なステークホルダーと購入基準
  • 主な会議とイベント
  • セラノスティクス市場の臨床調査データ

第6章 セラノスティクス市場：製品別

  • 画像診断
  • 放射性医薬品
  • IVD/バイオマーカースクリーニング
  • ソフトウェア&サービス

第7章 セラノスティクス市場：用途別

  • 前立腺癌
  • 骨転移
  • その他の癌
  • その他の用途

第8章 セラノスティクス市場：エンドユーザー別

  • 病院・癌治療センター
  • セラノスティクスセンター
  • 研究・学術センター

第9章 セラノスティクス市場：地域別

  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第10章 競合情勢

  • 概要
  • 主な戦略
  • 主要企業の採用戦略
  • 収益シェア分析
  • 市場シェア分析
  • 企業評価マトリックス
  • 新興企業/中小企業の評価マトリックス
  • 競合シナリオ・動向

第11章 企業プロファイル

  • 主要企業
    • ADVANCED ACCELERATOR APPLICATIONS
    • BAYER AG
    • GE HEALTHCARE
    • SIEMENS HEALTHINEERS AG
    • CARDINAL HEALTH
    • PHILIPS HEALTHCARE
    • CANON INC.
    • CURIUM
    • LANTHEUS
    • NORTHSTAR MEDICAL RADIOISOTOPES
    • ECKERT & ZIEGLER
    • PHARMALOGIC
    • ECZACIBASI-MONROL
    • ACROTECH BIOPHARMA, INC.
  • その他の企業
    • THERMO FISHER SCIENTIFIC INC.
    • GLOBAL MEDICAL SOLUTIONS
    • SHINE TECHNOLOGIES, LLC
    • ISOTOPIA MOLECULAR IMAGING LTD.
    • INSTITUTE OF ISOTOPES
    • CHINA ISOTOPE & RADIATION CORPORATION
    • YANTAI DONGCHENG PHARMACEUTICAL GROUP CO., LTD.
    • ATOMVIE
    • ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH
    • TELIX PHARMACEUTICALS LIMITED
    • BLUE EARTH DIAGNOSTICS
    • SOFIE BIOSCIENCES
    • THERAGNOSTICS

第12章 付録

目次
Product Code: PH 8913

Report Description

Scope of the Report
Years Considered for the Study2021-2028
Base Year2022
Forecast Period2023-2028
Units ConsideredValue (USD) Billion
SegmentsProduct, Application, End user, and Region
Regions coveredNorth America, Europe, Asia Pacific, Rest of the World

The global theranostics market is projected to reach USD 4.3 billion by 2028 from USD 2.1 billion in 2023, at a CAGR of 15.5% from 2023 to 2028. Factors such as rising baby boomer population and advances in research and development of radiopharmceuticals are responsible for the increasing growth of this market. Increasing research and development activities, rising number of clinical trials, and government initiatives attributes to the growth of theranostics market.

"The radiopharmaceuticals segment held the largest share of the market in 2022."

Based on product, the theranostics market is segmented into diagnostic imaging, radiopharmaceuticals, IVD/biomarker screening, and software and services. The radiopharmaceuticals segment held the largest market share in 2022. The large share of this segment can be attributed to the rising adoption of theranostics and increasing prevalence of chronic diseases such as cancer.

"The prostate cancer application segment is projected to register the highest CAGR of the theranostics market by application during the forecast period."

Based on application, the theranostics market is segmented into prostate cancer, bone metastasis, other cancer, and other applications. The prostate cancer application segment is projected to register the highest CAGR of the theranostics market from 2023 to 2028. Factors such as rising number of cancer population and ongoing clinical trials to know the benefits of theranostics for other applications are driving the market growth.

"The market in the Asia Pacific region is expected to witness the highest growth during the forecast period."

The theranostics market in the APAC region is expected to register the highest CAGR during the forecast period, primarily due to evolving healthcare infrastructure and increasing focus of major players in the region. The healthcare infrastructure in emerging economies, such as China and India is evolving at a rapid pace, leading to major investments by hospitals and other end users. These factors are anticipated to fuel the growth of theranostics market in this region.

A breakdown of the primary participants referred to for this report is provided below:

  • By Company Type: Tier 1-48%, Tier 2-36%, and Tier 3- 16%
  • By Designation: Director-level-14%, C-level-10%, and Others-76%
  • By Region: North America-40%, Europe-32%, Asia Pacific-20%, Rest of the World- 8%

The prominent players in the theranostics market Advanced Accelerator Applications (France), Bayer AG (Germany), GE Healthcare (US) among others.

Research Coverage

This report studies the theranostics market based on product, application, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their growth trends and forecasts the revenue of the market segments with respect to three main regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall theranostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.

This report provides insights on the following pointers:

  • Analysis of key drivers (growing geriatric population and rising prevalence of associated diseases, rising use of radiophamrceuticals, rising focus on precision medicine), restraints (short life of radiopharmceuticals, unfavourable reimbursement scenario), opportunities (growth opportunities in emerging countries, advances in research and development of radiopharmceuticals), and challenges (hospital budget cuts and high equipment costs) influencing the growth of the theranostics market
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the theranostics market
  • Market Development: Comprehensive information about lucrative markets-the report analyses the theranostics market across varied regions
  • Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the theranostics market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Advanced Accelerator Applications (France), Bayer AG (Germany), GE Healthcare (US).

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 INCLUSIONS & EXCLUSIONS
  • 1.4 MARKET SEGMENTATION
    • 1.4.1 MARKETS COVERED
    • 1.4.2 REGIONS COVERED
    • 1.4.3 YEARS CONSIDERED
    • 1.4.4 CURRENCY CONSIDERED
  • 1.5 RESEARCH LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 RECESSION IMPACT: THERANOSTICS MARKET

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN METHODOLOGY
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Primary sources
      • 2.1.2.2 Key industry insights
      • 2.1.2.3 Breakdown of primaries
    • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
    • 2.2.1 BOTTOM-UP APPROACH
      • 2.2.1.1 Approach 1: Company revenue estimation approach
    • FIGURE 5 COMPANY REVENUE ESTIMATION
    • FIGURE 6 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF BAYER AG
      • 2.2.1.2 Approach 2: Patient population-based market estimation
    • FIGURE 7 BOTTOM-UP APPROACH: THERANOSTICS MARKET
      • 2.2.1.3 Growth forecast
      • 2.2.1.4 CAGR projections
    • FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 9 DATA TRIANGULATION METHODOLOGY
    • 2.3.1 MARKET SHARE ESTIMATION
  • 2.4 STUDY ASSUMPTIONS
    • 2.4.1 MARKET ASSUMPTIONS
    • 2.4.2 GROWTH RATE ASSUMPTIONS
  • 2.5 RISK ASSESSMENT
    • TABLE 1 RISK ASSESSMENT: THERANOSTICS MARKET
  • 2.6 IMPACT OF ECONOMIC RECESSION ON THERANOSTICS MARKET

3 EXECUTIVE SUMMARY

    • FIGURE 10 THERANOSTICS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
    • FIGURE 11 THERANOSTICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 12 THERANOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    • FIGURE 13 REGIONAL SNAPSHOT OF THERANOSTICS MARKET

4 PREMIUM INSIGHTS

  • 4.1 THERANOSTICS MARKET OVERVIEW
    • FIGURE 14 RISING PREVALENCE OF CANCER AND GROWING FOCUS ON PRECISION MEDICINE TO DRIVE MARKET
  • 4.2 NORTH AMERICA: THERANOSTICS MARKET, BY PRODUCT (USD MILLION)
    • FIGURE 15 RADIOPHARMACEUTICALS TO COMMAND LARGEST MARKET SHARE IN NORTH AMERICAN THERANOSTICS MARKET DURING FORECAST PERIOD
  • 4.3 EUROPE: THERANOSTICS MARKET, BY APPLICATION (USD MILLION)
    • FIGURE 16 PROSTATE CANCER TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD
  • 4.4 ASIA PACIFIC: THERANOSTICS MARKET, BY END USER (USD MILLION)
    • FIGURE 17 HOSPITALS AND CANCER CARE CENTERS TO COMMAND LARGEST SHARE IN ASIA PACIFIC MARKET DURING FORECAST PERIOD
  • 4.5 GEOGRAPHIC SNAPSHOT: THERANOSTICS MARKET
    • FIGURE 18 CHINA TO WITNESS HIGHEST GROWTH RATE DURING STUDY PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 19 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: THERANOSTICS MARKET
    • 5.2.1 DRIVERS
      • 5.2.1.1 Growing geriatric population and rising prevalence of target diseases
      • 5.2.1.2 Increasing use of radiopharmaceuticals in neurological applications
      • 5.2.1.3 Growing focus on precision medicine
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Short half-life of radiopharmaceuticals
    • TABLE 2 PHYSICAL HALF-LIFE OF RADIOPHARMACEUTICALS
      • 5.2.2.2 Unfavorable healthcare reimbursement scenario
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growth opportunities in emerging economies
      • 5.2.3.2 Rising number of R&D programs for radiopharmaceuticals
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Hospital budget cuts and high equipment costs
  • 5.3 PRICING ANALYSIS
    • FIGURE 20 AVERAGE SELLING PRICE FOR RADIOPHARMACEUTICALS
    • TABLE 3 AVERAGE COST FOR THERANOSTICS TREATMENT, BY REGION
  • 5.4 VALUE CHAIN ANALYSIS
    • FIGURE 21 VALUE CHAIN ANALYSIS: THERANOSTICS MARKET
  • 5.5 ECOSYSTEM/MARKET MAP
  • 5.6 SUPPLY CHAIN ANALYSIS
    • 5.6.1 PROMINENT COMPANIES
    • 5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES
    • 5.6.3 END USERS
    • FIGURE 22 SUPPLY CHAIN ANALYSIS: THERANOSTICS MARKET
  • 5.7 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 4 PORTER'S FIVE FORCES ANALYSIS: THERANOSTICS MARKET
    • 5.7.1 INTENSITY OF COMPETITIVE RIVALRY
    • 5.7.2 BARGAINING POWER OF SUPPLIERS
    • 5.7.3 BARGAINING POWER OF BUYERS
    • 5.7.4 THREAT OF SUBSTITUTES
    • 5.7.5 THREAT OF NEW ENTRANTS
  • 5.8 REGULATORY LANDSCAPE
    • 5.8.1 NORTH AMERICA
      • 5.8.1.1 US
      • 5.8.1.2 Canada
    • 5.8.2 EUROPE
    • 5.8.3 ASIA PACIFIC
      • 5.8.3.1 Australia
      • 5.8.3.2 India
      • 5.8.3.3 China
    • 5.8.4 REST OF THE WORLD
      • 5.8.4.1 Turkey
      • 5.8.4.2 UAE
      • 5.8.4.3 South Africa
    • TABLE 5 REGULATORY AGENCIES AND GUIDELINES
  • 5.9 TIMELINE FOR THERANOSTICS MARKET
  • 5.10 REIMBURSEMENT ANALYSIS
    • TABLE 6 MEDICAL REIMBURSEMENT CODES FOR THERANOSTICS IN US, 2022
  • 5.11 TRADE ANALYSIS
    • 5.11.1 TRADE ANALYSIS FOR THERANOSTICS MARKET
    • TABLE 7 IMPORT DATA FOR RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2022 (USD THOUSAND)
    • TABLE 8 EXPORT DATA FOR RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2022 (USD THOUSAND)
  • 5.12 PATENT ANALYSIS
    • FIGURE 23 TOP 10 PATENT APPLICANTS FOR THERANOSTICS (JANUARY 2012-DECEMBER 2022)
  • 5.13 CASE STUDY ANALYSIS
    • TABLE 9 CASE STUDY 1: LUTETIUM-177-PSMA-617 FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
  • 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.14.1 KEY STAKEHOLDERS
    • TABLE 10 KEY STAKEHOLDERS AND THEIR REQUIREMENTS
    • 5.14.2 IMPACT ANALYSIS OF KEY BUYING CRITERIA
    • TABLE 11 IMPACT OF KEY STAKEHOLDERS ON BUYING CRITERIA
  • 5.15 KEY CONFERENCES & EVENTS
    • TABLE 12 LIST OF KEY CONFERENCES & EVENTS, 2023-2024
  • 5.16 CLINICAL RESEARCH DATA FOR THERANOSTICS MARKET

6 THERANOSTICS MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
    • TABLE 13 THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • 6.2 DIAGNOSTIC IMAGING
    • 6.2.1 EASY ANALYSIS OF DISEASE CONDITIONS AND ACCURATE THERAPIES TO DRIVE MARKET
    • TABLE 14 THERANOSTICS MARKET FOR DIAGNOSTIC IMAGING, BY REGION, 2021-2028 (USD MILLION)
  • 6.3 RADIOPHARMACEUTICALS
    • TABLE 15 THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 16 THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY REGION, 2021-2028 (USD MILLION)
    • 6.3.1 LUTETIUM-177
      • 6.3.1.1 Increasing incidence of neuroendocrine cancer to boost segment
    • TABLE 17 LUTETIUM-177 MARKET, BY REGION, 2021-2028 (USD MILLION)
      • 6.3.1.2 Samarium-153
      • 6.3.1.3 Rising incidence of bone metastasis to drive segment growth
    • TABLE 18 SAMARIUM-153 MARKET, BY REGION, 2021-2028 (USD MILLION)
      • 6.3.1.4 Radium-223
        • 6.3.1.4.1 Easy production of Radium-223 molecule to support market growth
    • TABLE 19 RADIUM-223 MARKET, BY REGION, 2021-2028 (USD MILLION)
      • 6.3.1.5 Iodine-131
        • 6.3.1.5.1 Increased applications in thyroid cancer and hyperthyroidism treatment to propel market
    • TABLE 20 IODINE-131 MARKET, BY REGION, 2021-2028 (USD MILLION)
      • 6.3.1.6 Yttrium-90
        • 6.3.1.6.1 Rising use in non-Hodgkin lymphoma and oncology radiotheranostics to drive segment
    • TABLE 21 YTTRIUM-90 MARKET, BY REGION, 2021-2028 (USD MILLION)
      • 6.3.1.7 Other radiopharmaceuticals
    • TABLE 22 OTHER RADIOPHARMACEUTICALS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 6.4 IVD/BIOMARKER SCREENING
    • 6.4.1 RISING ADOPTION OF THERANOSTICS TREATMENT TO SUPPORT MARKET GROWTH
    • TABLE 23 THERANOSTICS MARKET FOR IVD/BIOMARKER SCREENING, BY REGION, 2021-2028 (USD MILLION)
  • 6.5 SOFTWARE & SERVICES
    • 6.5.1 RISING USE OF NOVEL SOFTWARE AND INCREASING DEMAND FOR IMAGING SERVICES TO PROPEL MARKET
    • TABLE 24 THERANOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2021-2028 (USD MILLION)

7 THERANOSTICS MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
    • TABLE 25 THERANOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • 7.2 PROSTATE CANCER
    • 7.2.1 RISING INCIDENCE OF PROSTATE CANCER AMONG MEN TO FUEL MARKET
    • TABLE 26 THERANOSTICS MARKET FOR PROSTATE CANCER, BY REGION, 2021-2028 (USD MILLION)
  • 7.3 BONE METASTASIS
    • 7.3.1 INTRODUCTION OF NOVEL MEDICAL THERAPIES TO DRIVE MARKET
    • TABLE 27 THERANOSTICS MARKET FOR BONE METASTASIS, BY REGION, 2021-2028 (USD MILLION)
  • 7.4 OTHER CANCERS
    • TABLE 28 THERANOSTICS MARKET FOR OTHER CANCERS, BY REGION, 2021-2028 (USD MILLION)
  • 7.5 OTHER APPLICATIONS
    • TABLE 29 THERANOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)

8 THERANOSTICS MARKET, BY END USER

  • 8.1 INTRODUCTION
    • TABLE 30 THERANOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 8.2 HOSPITALS AND CANCER CARE CENTERS
    • 8.2.1 RISING TREND OF MODERNIZING IMAGING WORKFLOW SYSTEMS TO DRIVE MARKET
    • TABLE 31 THERANOSTICS MARKET FOR HOSPITALS AND CANCER CARE CENTERS, BY REGION, 2021-2028 (USD MILLION)
  • 8.3 THERANOSTICS CENTERS
    • 8.3.1 GROWING FOCUS ON TARGETED THERAPIES AND RISING PREVALENCE OF CHRONIC DISEASES TO PROPEL MARKET
    • TABLE 32 THERANOSTICS MARKET FOR THERANOSTICS CENTERS, BY REGION, 2021-2028 (USD MILLION)
  • 8.4 RESEARCH AND ACADEMIC CENTERS
    • 8.4.1 INCREASING COLLABORATIONS BETWEEN THERANOSTICS COMPANIES AND ACADEMIA TO SUPPORT MARKET GROWTH
    • TABLE 33 THERANOSTICS MARKET FOR RESEARCH AND ACADEMIC CENTERS, BY REGION, 2021-2028 (USD MILLION)

9 THERANOSTICS MARKET, BY REGION

  • 9.1 INTRODUCTION
    • TABLE 34 THERANOSTICS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 9.2 NORTH AMERICA
    • FIGURE 24 NORTH AMERICA: CANCER PREVALENCE, 2012-2020
    • FIGURE 25 NORTH AMERICA: THERANOSTICS MARKET SNAPSHOT (2022)
    • TABLE 35 NORTH AMERICA: THERANOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 36 NORTH AMERICA: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 37 NORTH AMERICA: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 38 NORTH AMERICA: THERANOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 39 NORTH AMERICA: THERANOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.3 NORTH AMERICA: RECESSION IMPACT
    • 9.3.1 US
      • 9.3.1.1 US to dominate North American theranostics market during forecast period
    • TABLE 40 US: KEY MACROINDICATORS
    • TABLE 41 US: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 42 US: THERANOSTICS MARKET RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • 9.3.2 CANADA
      • 9.3.2.1 Rising geriatric population and increasing number of initiatives for medical isotope development to drive market
    • TABLE 43 CANADA: KEY MACROINDICATORS
    • TABLE 44 CANADA: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 45 CANADA: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
  • 9.4 EUROPE
    • TABLE 46 EUROPE: THERANOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 47 EUROPE: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 48 EUROPE: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 49 EUROPE: THERANOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 50 EUROPE: THERANOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.1 EUROPE: RECESSION IMPACT
    • 9.4.2 GERMANY
      • 9.4.2.1 Well-established healthcare system and increased geriatric population to drive market
    • TABLE 51 GERMANY: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 52 GERMANY: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • 9.4.3 UK
      • 9.4.3.1 Increasing government funding in diagnostic imaging to support market growth
    • TABLE 53 UK: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 54 UK: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • 9.4.4 FRANCE
      • 9.4.4.1 Favorable government initiatives and high incidence of cancer to propel market
    • TABLE 55 FRANCE: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 56 FRANCE: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • 9.4.5 REST OF EUROPE
    • TABLE 57 REST OF EUROPE: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 58 REST OF EUROPE: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
  • 9.5 ASIA PACIFIC
    • FIGURE 26 ASIA PACIFIC: CANCER PREVALENCE, 2012-2020
    • FIGURE 27 ASIA PACIFIC: THERANOSTICS MARKET SNAPSHOT (2022)
    • TABLE 59 ASIA PACIFIC: THERANOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 60 ASIA PACIFIC: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 61 ASIA PACIFIC: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 62 ASIA PACIFIC: THERANOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 63 ASIA PACIFIC: THERANOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.5.1 ASIA PACIFIC: RECESSION IMPACT
    • 9.5.2 JAPAN
      • 9.5.2.1 Established nuclear medicine infrastructure and better accessibility of healthcare services to drive market
    • TABLE 64 JAPAN: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 65 JAPAN: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • 9.5.3 CHINA
      • 9.5.3.1 Increasing number of government initiatives and growing geriatric population to drive market
    • TABLE 66 CHINA: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 67 CHINA: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • 9.5.4 INDIA
      • 9.5.4.1 Rising number of nuclear medicine facilities and increasing incidence of chronic diseases to propel market
    • TABLE 68 INDIA: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 69 INDIA: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • 9.5.5 REST OF ASIA PACIFIC
    • TABLE 70 REST OF ASIA PACIFIC: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 71 REST OF ASIA PACIFIC: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
  • 9.6 REST OF THE WORLD
    • TABLE 72 REST OF THE WORLD: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 73 REST OF THE WORLD: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 74 REST OF THE WORLD: THERANOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 75 REST OF THE WORLD: THERANOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.6.1 REST OF THE WORLD: RECESSION IMPACT

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 KEY STRATEGIES/RIGHT TO WIN
  • 10.3 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN THERANOSTICS MARKET
    • FIGURE 28 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS IN THERANOSTICS MARKET
  • 10.4 REVENUE SHARE ANALYSIS
    • FIGURE 29 REVENUE SHARE ANALYSIS OF TOP THREE PLAYERS, 2020-2022
  • 10.5 MARKET SHARE ANALYSIS
    • FIGURE 30 ADVANCED ACCELERATOR APPLICATIONS COMMANDED LARGEST MARKET SHARE IN 2022
    • TABLE 76 DEGREE OF COMPETITION IN THERANOSTICS MARKET
  • 10.6 COMPANY EVALUATION MATRIX
    • 10.6.1 STARS
    • 10.6.2 EMERGING LEADERS
    • 10.6.3 PERVASIVE PLAYERS
    • 10.6.4 PARTICIPANTS
    • FIGURE 31 COMPANY EVALUATION MATRIX, 2022
    • 10.6.5 COMPANY FOOTPRINT
    • TABLE 77 PRODUCT AND REGIONAL FOOTPRINT
  • 10.7 START-UP/SME EVALUATION MATRIX
    • 10.7.1 PROGRESSIVE COMPANIES
    • 10.7.2 RESPONSIVE COMPANIES
    • 10.7.3 DYNAMIC COMPANIES
    • 10.7.4 STARTING BLOCKS
    • FIGURE 32 START-UP/SME EVALUATION MATRIX, 2022
    • 10.7.5 COMPETITIVE BENCHMARKING
    • TABLE 78 DETAILED LIST OF KEY START-UPS/SMES
  • 10.8 COMPETITIVE SCENARIOS & TRENDS

11 COMPANY PROFILES

  • 11.1 KEY PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 11.1.1 ADVANCED ACCELERATOR APPLICATIONS
    • TABLE 81 ADVANCED ACCELERATOR APPLICATIONS: COMPANY OVERVIEW
    • 11.1.2 BAYER AG
    • TABLE 82 BAYER AG: COMPANY OVERVIEW
    • FIGURE 33 BAYER AG: COMPANY SNAPSHOT (2022)
    • 11.1.3 GE HEALTHCARE
    • TABLE 83 GE HEALTHCARE: COMPANY OVERVIEW
    • FIGURE 34 GE HEALTHCARE: COMPANY SNAPSHOT (2022)
    • 11.1.4 SIEMENS HEALTHINEERS AG
    • TABLE 84 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
    • FIGURE 35 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)
    • 11.1.5 CARDINAL HEALTH
    • TABLE 85 CARDINAL HEALTH: COMPANY OVERVIEW
    • FIGURE 36 CARDINAL HEALTH: COMPANY SNAPSHOT (2022)
    • 11.1.6 PHILIPS HEALTHCARE
    • TABLE 86 PHILIPS HEALTHCARE: COMPANY OVERVIEW
    • FIGURE 37 PHILIPS HEALTHCARE: COMPANY SNAPSHOT (2022)
    • 11.1.7 CANON INC.
    • TABLE 87 CANON INC.: COMPANY OVERVIEW
    • FIGURE 38 CANON INC.: COMPANY SNAPSHOT (2022)
    • 11.1.8 CURIUM
    • TABLE 88 CURIUM: COMPANY OVERVIEW
    • 11.1.9 LANTHEUS
    • TABLE 89 LANTHEUS: COMPANY OVERVIEW
    • FIGURE 39 LANTHEUS: COMPANY SNAPSHOT (2022)
    • 11.1.10 NORTHSTAR MEDICAL RADIOISOTOPES
    • TABLE 90 NORTHSTAR MEDICAL RADIOISOTOPES: COMPANY OVERVIEW
    • 11.1.11 ECKERT & ZIEGLER
    • TABLE 91 ECKERT & ZIEGLER: COMPANY OVERVIEW
    • FIGURE 40 ECKERT & ZIEGLER: COMPANY SNAPSHOT (2022)
    • 11.1.12 PHARMALOGIC
    • TABLE 92 PHARMALOGIC: COMPANY OVERVIEW
    • 11.1.13 ECZACIBASI-MONROL
    • TABLE 93 ECZACIBASI-MONROL: COMPANY OVERVIEW
    • 11.1.14 ACROTECH BIOPHARMA, INC.
    • TABLE 94 ACROTECH BIOPHARMA, INC.: COMPANY OVERVIEW
  • 11.2 OTHER PLAYERS
    • 11.2.1 THERMO FISHER SCIENTIFIC INC.
    • 11.2.2 GLOBAL MEDICAL SOLUTIONS
    • 11.2.3 SHINE TECHNOLOGIES, LLC
    • 11.2.4 ISOTOPIA MOLECULAR IMAGING LTD.
    • 11.2.5 INSTITUTE OF ISOTOPES
    • 11.2.6 CHINA ISOTOPE & RADIATION CORPORATION
    • 11.2.7 YANTAI DONGCHENG PHARMACEUTICAL GROUP CO., LTD.
    • 11.2.8 ATOMVIE
    • 11.2.9 ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH
    • 11.2.10 TELIX PHARMACEUTICALS LIMITED
    • 11.2.11 BLUE EARTH DIAGNOSTICS
    • 11.2.12 SOFIE BIOSCIENCES
    • 11.2.13 THERAGNOSTICS
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

12 APPENDIX

  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3 CUSTOMIZATION OPTIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS